These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20533893)

  • 21. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
    Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
    J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melatonin in cardiovascular disease.
    Dominguez-Rodriguez A
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1593-6. PubMed ID: 22916801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.
    Bedini A; Spadoni G; Gatti G; Lucarini S; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Scaglione F
    J Med Chem; 2006 Dec; 49(25):7393-403. PubMed ID: 17149869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
    Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
    Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-Substituted anilides as selective melatonin MT2 receptor agonists.
    Epperson JR; Deskus JA; Gentile AJ; Iben LG; Ryan E; Sarbin NS
    Bioorg Med Chem Lett; 2004 Feb; 14(4):1023-6. PubMed ID: 15013015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-HT(7) receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009).
    Leopoldo M; Lacivita E; Berardi F; Perrone R
    Expert Opin Ther Pat; 2010 Jun; 20(6):739-54. PubMed ID: 20476847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P2X purinergic receptor ligands: recently patented compounds.
    Gunosewoyo H; Kassiou M
    Expert Opin Ther Pat; 2010 May; 20(5):625-46. PubMed ID: 20205618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers.
    Ayoub MA; Levoye A; Delagrange P; Jockers R
    Mol Pharmacol; 2004 Aug; 66(2):312-21. PubMed ID: 15266022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Farnesoid X receptor modulators: a patent review.
    Crawley ML
    Expert Opin Ther Pat; 2010 Aug; 20(8):1047-57. PubMed ID: 20569093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A novel therapeutic drug: ramelteon].
    Miyamoto M
    Nihon Rinsho; 2009 Aug; 67(8):1595-600. PubMed ID: 19768947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fresh from the pipeline: Ramelteon.
    Buysse D; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Nov; 4(11):881-2. PubMed ID: 16299918
    [No Abstract]   [Full Text] [Related]  

  • 33. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
    Rivara S; Mor M; Silva C; Zuliani V; Vacondio F; Spadoni G; Bedini A; Tarzia G; Lucini V; Pannacci M; Fraschini F; Plazzi PV
    J Med Chem; 2003 Apr; 46(8):1429-39. PubMed ID: 12672242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigational melatonin receptor agonists.
    Hardeland R
    Expert Opin Investig Drugs; 2010 Jun; 19(6):747-64. PubMed ID: 20408738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient synthesis of hexahydroindenopyridines and their potential as melatoninergic ligands.
    Párraga J; Moreno L; Diaz A; El Aouad N; Galán A; Sanz MJ; Caignard DH; Figadère B; Cabedo N; Cortes D
    Eur J Med Chem; 2014 Oct; 86():700-9. PubMed ID: 25232966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress towards novel adenosine receptor therapeutics gleaned from the recent patent literature.
    Press NJ; Fozard JR
    Expert Opin Ther Pat; 2010 Aug; 20(8):987-1005. PubMed ID: 20649373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melatonin-enhanced hyperactivation of hamster sperm.
    Fujinoki M
    Reproduction; 2008 Nov; 136(5):533-41. PubMed ID: 18715981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives.
    Ivachtchenko AV; Ivanenkov YA
    Expert Opin Ther Pat; 2012 Aug; 22(8):917-64. PubMed ID: 22816965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurokinin-1 receptor antagonists: a comprehensive patent survey.
    Huang SC; Korlipara VL
    Expert Opin Ther Pat; 2010 Aug; 20(8):1019-45. PubMed ID: 20533894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers.
    Niles LP; Armstrong KJ; Rincón Castro LM; Dao CV; Sharma R; McMillan CR; Doering LC; Kirkham DL
    BMC Neurosci; 2004 Oct; 5():41. PubMed ID: 15511288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.